contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

Cessatech

Cessatech A/S ("Cessatech" or the "Company") today releases its results for the period 1 January - 31 March 2024. The first quarter report is available as an attached document to this press ...

<div class="abstract"><p>Cessatech A/S ("Cessatech" or the "Company") today releases its results for the&nbsp;period 1 January - 31 March 2024. The first quarter report is available as an&nbsp;attached document to this press release and on www.cessatech.com under&nbsp;Investor/Filings &amp; Reports.&nbsp;</p></div>First quarter financial results 2024 (1 January - 31 March):&nbsp;<ul><li>Net revenue&nbsp;was KDKK 0</li><li>Operating result was KDKK -4.079&nbsp;</li><li>Net result was KDKK -2.711</li><li>Cash at bank end of the period was KDKK 15.041</li><li>Earnings per share* was KDKK -0,16</li><li>Solidity** was 95%&nbsp;</li></ul>The Company has advanced well with its planned activities<ul><li>US planning &amp; preparation for CT001 launch</li><li>CT001 device verification completed</li><li>Study 0202 initiation visits and supply of IMP medicine&nbsp;</li><li>Submission of abstract for unified PK-PD model in children&nbsp;</li></ul><p>*Earnings per share (DKK per share): Operating result divided by the average number of shares during the period. The total number of shares as of&nbsp;31&nbsp;March 2024 amounted to 17.425.094 shares, the average number of shares during the first quarter was 16.602.837&nbsp;<br>**Solidity: Total equity divided by total capital and liability&nbsp;</p><p>Comment from CEO, Jes Trygved:&nbsp;<br>Our focus has also very much been on the planning and&nbsp;preparation for the US launch of CT001 where we expect to have first packs shipped to&nbsp;selected US hospitals under the Early Access Program in just a few months. Thanks to&nbsp;teams for its efficiency, hard work and commitment for making this possible. We are also&nbsp;pleased to soon initiate the Paediatric Safety Study 0202, which is the final clinical trial&nbsp;before we can prepare for regulatory submission for CT001, and we have submitted an&nbsp;abstract on the paediatric population data, a PK-PD model, which will be presented end&nbsp;of June at a conference in Europe.&nbsp;</p>

Tilmeld dig vores nyhedsbrev - ingen konto nødvendig!